SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Larsson Rolf) "

Sökning: WFRF:(Larsson Rolf)

  • Resultat 1-10 av 581
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bülow Anderberg, Sara, et al. (författare)
  • Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients
  • 2021
  • Ingår i: Cytokine. - : Springer Nature. - 1043-4666 .- 1096-0023. ; 138
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The infection caused by SARS CoV-2 has been postulated to induce a cytokine storm syndrome that results in organ failure and even death in a considerable number of patients. However, the inflammatory response in Corona virus disease-19 (Covid-19) and its potential to cause collateral organ damage has not been fully elucidated to date. This study aims to characterize the acute cytokine response in a cohort of critically ill Covid-19 patients.METHOD: 24 adults with PCR-confirmed Covid-19 were included at time of admission to intensive care a median of eleven days after initial symptoms. Eleven adult patients admitted for elective abdominal surgery with preoperative plasma samples served as controls. All patients were included after informed consent was obtained. 27 cytokines were quantified in plasma. The expression of inflammatory mediators was then related to routine inflammatory markers, SAPS3, SOFA score, organ failure and 30-day mortality.RESULTS: A general increase in cytokine expression was observed in all Covid-19 patients. A strong correlation between respiratory failure and IL-1ra, IL-4, IL-6, IL-8 and IP-10 expression was observed. Acute kidney injury development correlated well with increased levels of IL-1ra, IL-6, IL-8, IL-17a, IP-10 and MCP-1. Generally, the cohort demonstrated weaker correlations between cytokine expression and 30-day mortality out of which IL-8 showed the strongest signal in terms of mortality.CONCLUSION: The present study found that respiratory failure, acute kidney injury and 30-day mortality in critically ill Covid-19 patients are associated with moderate increases of a broad range of inflammatory mediators at time of admission.
  •  
2.
  • Carlier, Charlotte, et al. (författare)
  • Preclinical activity of melflufen (J1) in ovarian cancer
  • 2016
  • Ingår i: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 7:37, s. 59322-59335
  • Tidskriftsartikel (refereegranskat)abstract
    • Ovarian cancer carries a significant mortality. Since symptoms tend to be minimal, the disease is often diagnosed when peritoneal metastases are already present. The standard of care in advanced ovarian cancer consists of platinum-based chemotherapy combined with cytoreductive surgery. Unfortunately, even after optimal cytoreduction and adjuvant chemotherapy, most patients with stage III disease will develop a recurrence. Intraperitoneal administration of chemotherapy is an alternative treatment for patients with localized disease. The pharmacological and physiochemical properties of melflufen, a peptidase potentiated alkylator, raised the hypothesis that this drug could be useful in ovarian cancer and particularily against peritoneal carcinomatosis. In this study the preclinical effects of melflufen were investigated in different ovarian cancer models. Melflufen was active against ovarian cancer cell lines, primary cultures of patient-derived ovarian cancer cells, and inhibited the growth of subcutaneous A2780 ovarian cancer xenografts alone and when combined with gemcitabine or liposomal doxorubicin when administered intravenously. In addition, an intra-and subperitoneal xenograft model showed activity of intraperitoneal administered melflufen for peritoneal carcinomatosis, with minimal side effects and modest systemic exposure. In conclusion, results from this study support further investigations of melflufen for the treatment of peritoneal carcinomatosis from ovarian cancer, both for intravenous and intraperitoneal administration.
  •  
3.
  • Christensen, Kjeld, et al. (författare)
  • Effects on blood compatibility in vitro by combining a direct P2Y(12) receptor inhibitor and heparin coating of stents
  • 2006
  • Ingår i: Platelets. - : Informa UK Limited. - 0953-7104 .- 1369-1635. ; 17:5, s. 318-327
  • Tidskriftsartikel (refereegranskat)abstract
    • The effect of the direct platelet P2Y12 receptor inhibitor, AR-C69931MX, on activation of blood induced by stents with and without heparin coating was investigated using a whole blood Chandler loop model in vitro . Stents were deployed in Chandler loops. Fresh human blood with heparin and AR-C69931MX was rotated for 1 h at 37°C and used for measurements of platelets, microparticles, thrombin-antithrombin complex (TAT), fibrinogen binding to platelets, P-selectin expression by platelets, CD11b, Prothrombin Fragment F1+2, FXIa-AT, FXIIa-AT, C3a, sC5b-9 and stent score. In the first experiment there were four study groups with unmodified stents: 1a, no AR-C69931MX; 1b, 250 nmol/L; 1c, 750 nmol/L; 1d, 2250 nmol/L of AR-C69931MX. In the second experiment the concentration of AR-C69931MX was 500 nmol/L: 2a; tubings without stent; 2b; tubings with heparin-coated stent; 2c; tubings with unmodified stents. Heparin-coated stents were used in the third experiment: 3a; no AR-C69931MX; 3b; 500 nmol/L of AR-C69931MX. In the first experiment there were significant differences in all parameters analysed except for C3a, and stent score when the group with no AR-C69931MX was compared to all the groups with AR-C69931MX. In the second experiment there were significant differences in platelet count, TAT, FXIa-AT, FXIIa-AT and stent score when unmodified stents were compared to loops with no stents and partly to loops with heparin-coated stents. In the third experiment there was a significant reduction in generation of TAT, stent score and better preservation of platelet number by combining the platelet inhibitor and heparin-coated stents as compared to heparin-coated stents alone. The conclusion is that the direct P2Y12 receptor inhibitor AR-C69931MX reduced the different aspects of activation of blood induced by both unmodified and heparin-coated stents.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Gullbo, Joachim, et al. (författare)
  • Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-melphalanyl-p-L-fluorophenylalanine ethyl ester) : Comparison with its m-L-sarcolysin analogue P2
  • 2003
  • Ingår i: Molecular Cancer Therapeutics. - 1535-7163 .- 1538-8514. ; 2:12, s. 1331-1339
  • Tidskriftsartikel (refereegranskat)abstract
    • Peptichemio (PTC), a mixture of six oligopeptides all containing m-L-sarcolysin, has previously shown impressive results in clinical trials. The tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester) has been suggested as the main contributor to PTC activity. In contrast to its analogue melphalan, m-L-sarcolysin never reached clinical use. To allow a direct comparison, the corresponding melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester) was synthesized and its activity was compared with that of P2; the activities of melphalan and m-L-sarcolysin were studied in parallel. Cytotoxic activity in human tumor cell lines and some fresh human tumor specimens were analyzed as well as effects on cellular metabolism, macromolecular synthesis, and preliminary evaluation of the cell death characteristics. The results show that melphalan and m-L-sarcolysin display similar activity in these systems and that the tripeptides were more active than their parent monomers. Surprisingly however, the melphalan containing tripeptide J3 demonstrated a significantly more rapid and stronger activity than the m-L-sarcolysin analogue P2. Finally, the in vivo toxicity and activity of melphalan and J3 were investigated in mice bearing human leukemia cells in s.c. fibers. The in vitro results seem translatable into the in vivo situation, demonstrating better antileukemic effect of J3 but similar side effects as melphalan.
  •  
10.
  • Gullbo, Joachim, et al. (författare)
  • Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
  • 2004
  • Ingår i: Investigational new drugs. - 0167-6997. ; 22:4, s. 411-20
  • Tidskriftsartikel (refereegranskat)abstract
    • The novel alkylating dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) was evaluated for acute toxicity and antitumor activity in mice, with melphalan as a reference. To determine a safe and tolerable dose for efficacy studies the acute toxicity following intravenous injection in the tail vein was monitored using a 14-day schedule with up to four doses. The highest tested dose, 25 micromoles/kg, was considered close to this level, with minor effects on body weight gain but significant effects on hematological parameters. Melphalan and J1 appeared equitoxic with no statistically significant differences. Subsequently a mouse hollow fiber model was employed with subcutaneous implantation of fibers containing human tumor cells. Three different human tumor cell lines as well as two samples of primary human tumor cells (ovarian carcinoma and chronic lymphatic leukemia) were used as tumor models. At the dose level tested there was a marked and statistically significant decrease in both T-cell leukemia CCRF-CEM and small cell lung cancer NCI-H69 tumor cell growth and viability in response to J1 as compared with both placebo and melphalan treated groups. In primary ovarian carcinoma cells only J1 treatment resulted in significant tumor regression (net cell kill). In summary the results indicate that, despite an expected short half time in the blood circulation, the promising in vitro data from the previous studies of J1 seems translatable into the in vivo situation. At equal doses of alkylating units J1, compared to melphalan, was more active in the mouse hollow-fiber model, but showed similar general toxicity.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 581
Typ av publikation
tidskriftsartikel (389)
doktorsavhandling (44)
annan publikation (34)
rapport (30)
konferensbidrag (24)
bok (20)
visa fler...
bokkapitel (18)
licentiatavhandling (9)
samlingsverk (redaktörskap) (5)
forskningsöversikt (4)
patent (3)
proceedings (redaktörskap) (1)
visa färre...
Typ av innehåll
refereegranskat (391)
övrigt vetenskapligt/konstnärligt (175)
populärvet., debatt m.m. (15)
Författare/redaktör
Larsson, Rolf (425)
Nygren, Peter (134)
Fryknäs, Mårten (80)
Gullbo, Joachim (64)
Lindhagen, Elin (33)
Rickardson, Linda (29)
visa fler...
Jarvius, Malin (26)
Linder, Stig (24)
Andersson, Claes (21)
Wickström, Malin (21)
Lövborg, Henrik (21)
Nilsson, Bo (19)
Höglund, Martin (19)
Senkowski, Wojciech (18)
Jonsson, Elin (18)
Larsson, Rolf, Profe ... (17)
Gustafsson, Mats (16)
Gustafsson, Mats G. (16)
Dhar, Sumeer (16)
Åleskog, Anna (16)
Bohlin, Lars (15)
Larsson, Anders (14)
Elgue, Graciela (14)
Larsson, Rolf, 1962- (14)
Isaksson, Anders (13)
Lönnerholm, Gudmar (12)
Forestier, Erik (11)
Karlsson, Mats O. (11)
Djurfeldt, Göran (11)
Zhang, Xiaonan (11)
Blom, Kristin (11)
Sanchez, Javier (11)
Korsgren, Olle (10)
Berndtsson, Ronny (10)
Jirström, Magnus (10)
Adolfsson, Rolf (10)
Larsson, Lars, 1945 (10)
Frost, Britt-Marie (10)
Lewensohn, Rolf (9)
D'Arcy, Padraig (9)
Ekelund, Sara (9)
Larsson, Lars (8)
Palle, Josefine (8)
Nilsson Ekdahl, Kris ... (8)
Hassan, Saadia (8)
Nilsson, Kenneth (8)
Nilsson, Lars-Göran (8)
Berglund, Malin (8)
Aspegren, Henrik (8)
Strese, Sara (8)
visa färre...
Lärosäte
Uppsala universitet (388)
Lunds universitet (80)
Karolinska Institutet (68)
Linköpings universitet (25)
Linnéuniversitetet (22)
Umeå universitet (19)
visa fler...
Stockholms universitet (18)
Göteborgs universitet (16)
Luleå tekniska universitet (15)
Chalmers tekniska högskola (15)
Örebro universitet (7)
Kungliga Tekniska Högskolan (6)
Naturvårdsverket (6)
Sveriges Lantbruksuniversitet (6)
Malmö universitet (4)
RISE (4)
Jönköping University (2)
Högskolan i Gävle (1)
Mälardalens universitet (1)
Högskolan i Skövde (1)
Södertörns högskola (1)
Gymnastik- och idrottshögskolan (1)
Karlstads universitet (1)
Försvarshögskolan (1)
Kungl. Konsthögskolan (1)
visa färre...
Språk
Engelska (492)
Svenska (46)
Odefinierat språk (35)
Norska (3)
Tyska (1)
Italienska (1)
visa fler...
Polska (1)
Japanska (1)
Koreanska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (172)
Naturvetenskap (83)
Samhällsvetenskap (71)
Teknik (62)
Humaniora (12)
Lantbruksvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy